BTK and autoimmune thrombocytopenic purpura: Preliminary clinical trials and observational studies have demonstrated encouraging results with both SYK and BTK inhibitors in adult ITP, including acceptable safety profiles and clinically meaningful platelet responses in patients refractory to standard treatments.6,7